Title : A Proposed Evidence-Based Local Guideline for Definition of Multidrug-Resistant (MDR), Extensively Drug-Resistant (XDR) and Pan Drug-Resistant (PDR) Bacteria by the Microbiology Laboratory

Vol 4 No 3 (2021): Volume 04 Issue 03 March 2021

Article Date Published : 2 March 2021 | Page No.: 146-153 | Google Scholar | Crossref doi for this article

Abstract :

Multi-drug resistant organisms (MDROs) are defined as microorganisms, predominantly bacteria, that are resistant to one or more classes of antimicrobial agents. These pathogens are frequently resistant to most available antimicrobial agents and deserve special attention in healthcare facilities. Generally, MDRO infections have clinical manifestations similar to infections caused by susceptible pathogens. Despite of two different classifications by WHO and CDC, still there are debates about update definition of MDROs in medical literature. Here we provide an updated local guideline for definitions of various MDROs by microbiology laboratory

Keywords :

Antimicrobial agent, Healthcare facilities, microbiology laboratory, Multi-drug resistant organisms (MDROs)

References :

  1. European Commission Action plan against the rising threats from antimicrobial resistance: Communication from the Commission to the European Parliament and the Council. 15 Brussels, 2011.
  2. The bacterial challenge: time to react. ECDC/EMEA joint technical report. EMEA Doc. Ref. EMEA/576176/2009. Stockholm, September 2009. ISBN 978-92-9193-193-4 Available: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf [Accessed March 2019].
  1. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
  2. https://www.cdc.gov
  3. https://www.clsi.org
  4. https://www.eucast.org
  5. German GJ, Gilmour M, Tipples G, et al. Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. Can Commun Dis Rep. 2018;44(1):29-34. Published 2018 Jan 4. doi:10.14745/ccdr. v44i01a07
  6. German GJ, Jamieson FB, Gilmour M, Almohri H, Bullard J, Domingo MC et al. Interim recommendations for the reporting of extensively drug resistant and pan-drug resistant isolates of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp. and Stenotrophomonas maltophilia. Can Commun Dis Rep 2016;42(4):91–7. Available from: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2016-42/ccdr-volume-42-4-april-7-2016/ccdr-volume-42-4-april-7-2016-vaccine-preventable-diseases-3.html
  1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012; 18:268–281.
  2. Leski TA, Vora GJ, Barrows BR, Piemental G, House BL, Nicklasson M. et al. Molecular Characterization of Multidrug Resistant Hospital Isolates Using the Antimicrobial Resistance Determinant Microarray. PLoS One. 2013;8: e69507.
  3. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004; 10: S122–9.
  4. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan drug resistant Acinetobacter. Scand J Infect Dis. 2005; 37:195–9.
  5. Gould IM, Wang GQ, Wu JJ, Lim VK, Hutchinson J, Walsh T, Turnidge J. MDRO Beijing Consensus Meeting Report: Global burden of multidrug-resistant organisms’ current antimicrobial resistance problems in Asia-Pacific. J Glob Antimicrob Resist. 2014 Mar;2(1):7-9. doi: 10.1016/j.jgar.2013.10.005. Epub 2013 Nov 8. PMID: 27873642.
  6. Anaya-Baz B, Maldonado N, Palacios-Baena ZR, Palomo V, Pezzani MD, Chiesi S, Razzaboni E, Compri M, Tacconelli E, Rodriguez-Baño J. Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol. BMJ Open. 2020 May 5;10(5): e030608. doi: 10.1136/bmjopen-2019-030608. PMID: 32371505; PMCID: PMC7228488.
  7. Sun W, Hesse S, Xu M, Childs RW, Zheng W, Williamson PR. “Real-Time” High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report. Front Med (Lausanne). 2018 Sep 20;5: 267. doi: 10.3389/fmed.2018.00267. PMID: 30298132; PMCID: PMC6160733.
  8. Burnham JP, Kwon JH, Olsen MA, Babcock HM, Kollef MH. Readmissions with Multidrug-Resistant Infection in Patients with Prior Multidrug Resistant Infection. Infect Control Hosp Epidemiol. 2018 Jan;39(1):12-19. doi: 10.1017/ice.2017.254. Epub 2017 Dec 17. PMID: 29248023; PMCID: PMC6233291.
  9. Kalluru S, Eggers S, Barker A, Shirley D, Sethi AK, Sengupta S, Yeptho K, Safdar N. Risk factors for infection with multidrug-resistant organisms in Haryana, India. Am J Infect Control. 2018 Mar;46(3):341-345. doi: 10.1016/j.ajic.2017.08.021. Epub 2017 Nov 1. PMID: 29102426; PMCID: PMC6055232.
  10. Spachmann PJ, May M, Vetterlein MW, Fritsche HM, Steffen S, Schostak M, Wagenlehner FM, Burger M, Weylandt KH, Salzberger B, Brookman-May SD, Gilfrich C; MR2 study group. Awareness and perception of multidrug-resistant organisms and antimicrobial therapy among internists vs. surgeons of different specialties: Results from the German MR2 Survey. Caspian J Intern Med. 2019 Spring;10(2):132-141. doi: 10.22088/cjim.10.2.132. PMID: 31363391; PMCID: PMC6619476.
  11. Han JH, Lapp Z, Bushman F, Lautenbach E, Goldstein EJC, Mattei L, Hofstaedter CE, Kim D, Nachamkin I, Garrigan C, Jain T, Bilker W, Wolford HM, Slayton RB, Wise J, Tolomeo P, Snitkin ES. Whole-Genome Sequencing to Identify Drivers of Carbapenem-Resistant Klebsiella pneumoniae Transmission within and between Regional Long-Term Acute-Care Hospitals. Antimicrob Agents Chemother. 2019 Oct 22;63(11): e01622-19. doi: 10.1128/AAC.01622-19. PMID: 31451495; PMCID: PMC6811406.
  12. Chen LF, Knelson LP, Gergen MF, Better OM, Nicholson BP, Woods CW, Rutala WA, Weber DJ, Sexton DJ, Anderson DJ; CDC Prevention Epicenters Program. A prospective study of transmission of Multidrug-Resistant Organisms (MDROs) between environmental sites and hospitalized patients-the TransFER study. Infect Control Hosp Epidemiol. 2019 Jan;40(1):47-52. doi: 10.1017/ice.2018.275. Epub 2018 Nov 14. PMID: 30426908; PMCID: PMC6690181.
  13. Girija As S, Priyadharsini J V. CLSI based antibiogram profile and the detection of MDR and XDR strains of Acinetobacter baumannii isolated from urine samples. Med J Islam Repub Iran. 2019; 33:3. Published 2019 Feb 8. doi:10.34171/mjiri.33.3
  14. Khan F, Khan A, Kazmi SU. Prevalence and Susceptibility Pattern of Multi Drug Resistant Clinical Isolates of Pseudomonas aeruginosa in Karachi. Pakistan Journal of Medical Sciences. 2014 Sep;30(5):951-954. DOI: 10.12669/pjms.305.5400.
  15. Alyssa R. Golden, Margot Rosenthal, Ben Fultz, Kimberly A. Nichol, Heather J. Adam, Matthew W. Gilmour, Melanie R. Baxter, Daryl J. Hoban, James A. Karlowsky, George G. Zhanel, Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007–13, Journal of Antimicrobial Chemotherapy, Volume 70, Issue 8, August 2015, Pages 2199–2202, https://doi.org/10.1093/jac/dkv107
  16. Basak S, Singh P, Rajurkar M. Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study. J Pathog. 2016; 2016:4065603. doi:10.1155/2016/4065603

How to Cite :

A Proposed Evidence-Based Local Guideline for Definition of Multidrug-Resistant (MDR), Extensively Drug-Resistant (XDR) and Pan Drug-Resistant (PDR) Bacteria by the Microbiology Laboratory. Arash Eatemadi, Elham Al Risi, Amit Kasilas Kasliwal, Ahmed Al Zaˊabi, Hamid Moradzadegan, Zahra Aslani , 4(3), 146-153. Retrieved from https://ijcsrr.org/single-view/?id=3519&pid=3516

Most read articles by the same author(s)

Arash Eatemadi, Elham Al Risi, Amit Kasilas Kasliwal, Ahmed Al Zaˊabi, Hamid Moradzadegan, Zahra Aslani,

View

312

Citation

Downloads

Article Details